TP024/#446 Upgrade: phase 1 combination trial of the NAPI2B-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UPRI; XMT-1536) in patients with ovarian cancer
Hays, John, Werner, Theresa, Lakhani, Nehal, Edenfield, Jeffrey, Buscema, Joseph, Burns, Timothy, Carrington, Cassandra, Keeton, Erika, Burger, Robert, Anderson, Charles
Published in International journal of gynecological cancer (04.12.2022)
Published in International journal of gynecological cancer (04.12.2022)
Get full text
Journal Article
Upgrade: Phase 1 combination trial of the NaPi2b-directed dolaflexin antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer (588)
Lakhani, Nehal, Burns, Timothy, Barve, Minal, Edenfield, Jeffery, Hays, John, Zarwan, Corrine, Werner, Theresa, Anderson, Charles, Buscema, Joseph, Bernardo, Patricia, Keeton, Erika, Carrington, Cassandra, Burger, Robert
Published in Gynecologic oncology (01.08.2022)
Published in Gynecologic oncology (01.08.2022)
Get full text
Journal Article
UPGRADE-A: Phase 1 expansion trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi) in combination with carboplatin in patients with high-grade serous ovarian cancer (HGSOC)
Hays, John L., Friedman, Claire Frances, Lakhani, Nehal, Anderson, Charles K, Buscema, Joseph, Duska, Linda R., Hamilton, Erika P., Taylor, Sarah E., Carrington, Cassandra, Burger, Robert Allen, Werner, Theresa Louise
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
32 UPGRADE: phase 1 combination trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer
Werner, Theresa L., Lakhani, Nehal, Edenfield, William, Hays, John, Zarwan, Corrine, Buscema, Joseph, Burns, Timothy, Carrington, Cassandra, Keeton, Erika K., Burger, Robert A., Anderson, Charles
Published in Gynecologic oncology reports (01.12.2022)
Published in Gynecologic oncology reports (01.12.2022)
Get full text
Journal Article